Jonathan Wade Goldman
University of California, Los Angeles · 760 works · 35,214 citations · h-index 70
Top works
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
- Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
- Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology